Work

Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347

Year: 2019

Type: conference-abstract

Source: Clinical Research (Excluding Clinical Trials)

DOI: 10.1158/1538-7445.sabcs18-4881

Authors: Anthony J. Iafrate, Darrell R. Borger, Ana Vivancos, Martin Voss, James Cleary, Funda Meric-Bernstam, Josep Tabernero, Keith Flaherty, Nobuya Ishii, Franck Brichory, Hiroaki Tanaka, Anna Pokorska-Bocci, Jose Baselga, Paolo Nuciforo

Institutions: Massachusetts General Hospital, Takeda Oncology (United States), Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Chugai Pharmaceutical Co., Ltd. (Japan), Debiopharm (Switzerland)

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4234995169

Cites:

Cited by:

Related to: 10